Observational evidence from Indian nephrology practice
on desidustat in CKD-related anaemia.
Retrospective, multicentre observational study (2026)
Observational evidence shows association during treatment.
It does not establish causality as in randomised clinical trials.
Gulati S, Pahari D, Saraf K, et al.
Cureus. 2026 May; 18(5): e109574.
DOI: 10.7759/cureus.109574Total evaluable
patients
Non-dialysis
(NDD) patients
Dialysis-dependent
(DD) patients
Mean age
(years)
Patients with
diabetes
Patients with
hypertension
Within-patient change over time (association during treatment)
All within-patient changes from baseline were statistically significant, p < 0.005.
Results reflect association during treatment, not causality.
Compare haemoglobin change by care setting
Both groups showed significant improvement from baseline (p < 0.005).
Between-group difference was not statistically significant at any time point.
88.18% received desidustat 100 mg
three times weekly.
Iron therapy (oral/IV) was prescribed
according to clinical need and iron status.
No discontinuations due to drug-related
toxicity were documented during the
observation period.
Observed practice reflects real-world prescribing.
Please review the approved dosing in the Oxemia® PI.
Desidustat was generally well tolerated.
Mild events such as constipation and
throat discomfort were reported.
No serious adverse events attributable
to desidustat were reported.
No new safety signals were reported
during the observation period.
For a complete list of adverse events,
please read the full publication.
(Desidustat)
Please refer to the approved prescribing
information for:
This large real-world study adds important evidence of
sustained haemoglobin improvement with desidustat in
routine Indian nephrology practice across both dialysis
and non-dialysis care settings.
Source: Gulati S, et al. Cureus. 2026;18(5):e109574. DOI: 10.7759/cureus.109574 Open DOI